Glucose intolerance in aging male igfbp-3 transgenic mice: Differential effects of human igfbp-3 and its mutant igfbp-3 devoid of igf binding ability

Endocrinology (United States)

Volumn 156, Issue 2, 2015, Pages 462-474

  Hoa Nguyen, K ^a   Yao, Xing Hai ^a   Erickson, Adam G ^a   Mishra, Suresh ^a   Gregoire Nyomba B L ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FATTY ACID; GLUCOSE; GLYCEROL; HORMONE SENSITIVE LIPASE; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR-1, MOUSE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; FAT MASS; GENOTYPE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLYCEROL BLOOD LEVEL; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID HOMEOSTASIS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OBESITY; PANCREAS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; SKELETAL MUSCLE; TRANSGENIC MOUSE; WILD TYPE; ADIPOSE TISSUE; AGING; ANIMAL; BLOOD; FEMALE; GENETICS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; LIPID METABOLISM; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; AGING; ANIMALS; BODY WEIGHT; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; LIPIDS; MALE; MICE, TRANSGENIC; PANCREAS;

EID: 84921670837     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1271     Document Type: Article

References (52)

1. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41:425-443, vii-viii.
2. Martin JL, Baxter RC. Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors. 2011; 29:235-244
3. Clemmons DR, Moses AC, Sommer A, et al. Rh/IGF-1/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res. 2005;15:265-274
4. Regan FM, Williams RM, McDonald A, et al. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J Clin Endocrinol Metab 2010;95:2113-2122
5. Rajpathak SN, He M, Sun Q, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012;61:2248-2254
6. MuzumdarRH,MaX, Fishman S, et al. Central and opposing effects of IGF-1 and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006;55:2788-2796
7. Kim HS, Ali O, Shim M, et al. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res. 2007;61:159-164
8. Silha JV, Gui Y, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab. 2002;283:E937-E945
9. Nguyen KH, Yao XH, Moulik S, Mishra S, Nyomba BL. Human IGF binding protein-3 overexpression impairs glucose regulation in mice via an inhibition of insulin secretion. Endocrinology. 2011; 152:2184-2196
10. Yamada PM ,MehtaHH,HwangD, Roos KP, Hevener AL, Lee KW. EviDence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology. 2010;151: 5741-5750
11. Galarraga M, Campin J, Muoz-Barrutia A, et al. Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections. J Lipid Res. 2012;53:2791-2796
12. Hwang DL, Lee PD, Cohen P. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res. 2008;18: 65-74
13. Chan SS, Twigg SM, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 2005;90:6588-6595
14. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314-322
15. Cannon B, NeDergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277-359
16. Boucher J, Mori MA, Lee KY, et al. Impaired thermogenesis and adipose tissue Development in mice with fat-specific disruption of insulin and IGF-1 signalling. Nat Commun. 2012;3:902
17. Guerra C, Benito M, FernnDez M. IGF-1 induces the uncoupling protein gene expression in fetal rat brown adipocyte primary cultures: role of C/EBP transcription factors. Biochem Biophys Res Commun. 1994;201:813-819
18. Oh Y, Mller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem. 1993;268:26045-26048
19. Liu B, Lee HY, Weinzimer SA, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoidX receptor-Alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000;275:33607-33613
20. Buckway CK, Wilson EM, Ahlsn M, Bang P, Oh Y, Rosenfeld RG. Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab. 2001;86:4943-4950
21. Chen X, Ferry RJ Jr. Novel actions of IGFBP-3 on intracellular signaling pathways of insulin-secreting cells. Growth Horm IGF Res. 2006;16:41-48
22. Yan X, Forbes BE, McNeil KA, Baxter RC, Firth SM. Role of N-And C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem. 2004;279:53232-53240
23. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology. 2005; 146:1523-1531
24. Crossey PA, Jones JS, Miell JP. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes. 2000;49:457-465
25. Klting N, Koch L, WunDerlich T, et al. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes. 2008;57:2074-2082
26. Rogers NH, Landa A, Park S, Smith RG. Aging leads to a programmed loss of brown adipocytes in murine subcutaneous white adipose tissue. Aging Cell. 2012;11:1074-1083
27. Modric T, Silha JV, Shi Z, et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology. 2001;142:1958-1967
28. McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH. NIH experiment in centralized mouse phenotyping: the VanDerbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Physiol Endocrinol Metab. 2009;297:E849-E855
29. Nammi S, Dembele K, Nyomba BL. Increased 11beta-hydroxysteroid Dehydrogenase type-1 and hexose-6-phosphate Dehydrogenase in liver and adipose tissue of rat offspring exposed to alcohol in utero. Am J Physiol Regul Integr Comp Physiol. 2007;292: R1101-R1109
30. Seale P, Kajimura S, Spiegelman BM. Transcriptional control of brown adipocyte Development and physiological function-of mice and men. Genes Dev. 2009;23:788-797
31. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell. 2007;131:242-256
32. Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse moDel of type 2 diabetes: eviDence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52:2304-2314
33. Cortez MY, Torgan CE, Brozinick JT Jr, Ivy JL. Insulin resistance of obese Zucker rats exercise trained at two different intensities. Am J Physiol. 1991;261:E613-E619
34. Hgl SR, White MF, RhoDes CJ. Insulin-like growth factor I (IGF-1)-stimulated pancreatic beta-cell growth is glucose-DepenDent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-1 in INS-1 cells. J Biol Chem. 1998;273:17771-17779
35. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. Beta cell expression of IGF-1 leads to recovery from type 1 diabetes. J Clin Invest. 2002;109:1153-1163
36. Palau N, Rebuffat SA, Altirriba J, et al. Role of IGFBP-3 in the regulation of-cell mass during obesity: adipose tissue/-cell cross talk. Endocrinology. 2012;153:177-187
37. Friedrich N, Nauck M, Schipf S, Vlzke H, Brabant G, Wallaschofski H. Cross-sectional and longitudinal associations between insulin-like growth factor I and metabolic syndrome: a general population study in German adults. Diabetes Metab Res Rev. 2013;29: 452-462
38. Friedrich N, Thuesen B, JOrgensen T, et al. The association between IGF-1 and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35:768-773
39. Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab. 2009;296:E654-E663
40. Fanayan S, Firth SM, Baxter RC. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem. 2002;277:7255-7261
41. Scavo LM, Karas M, Murray M, Leroith D. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab 2004;89:3543-3553
42. De Silva HC, Firth SM, Twigg SM, Baxter RC. Interaction between IGF binding protein-3 and TGF in the regulation of adipocyte differentiation. Endocrinology. 2012;153:4799-4807
43. Fritton JC, Kawashima Y, Mejia W, et al. The insulin-like growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate. J Biol Chem. 2010;285:4709-4714
44. Grohmann M, Sabin M, Holly J, Shield J, Crowne E, Stewart C. Characterization of differentiated subcutaneous and visceral adipose tissue from children: the influences of TNF-Alpha and IGF-1. J Lipid Res. 2005;46:93-103
45. Courtland HW, DeMambro V, Maynard J, et al. Sex-specific regulation of body size and bone slenDerness by the acid labile subunit. J Bone Miner Res. 2010;25:2059-2068
46. Domen HM, Hwa V, Jasper HG, Rosenfeld RG. Acid-labile subunit (ALS) Deficiency. Best Pract Res Clin Endocrinol Metab. 2011; 25:101-113
47. Hgler W, Martin DD, Crabtree N, et al. IGFALS gene dosage effects on serum IGF-1 and glucose metabolism, body composition, bone growth in length and width, and the pharmacokinetics of recombinant human IGF-1 administration. J Clin Endocrinol Metab. 2014;99(4):E703-12
48. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferatoractivated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-367
49. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-1280
50. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulinlike growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-497
51. Le Marchand L, Kolonel LN, HenDerson BE, Wilkens LR. Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: the multiethnic cohort study. Cancer EpiDemiol Biomarkers Prev. 2005;14:1319-1321
52. Mong JL, Ng MC, Guldan GS, et al. Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-1 activity and lipid parameters in adolescents. Int J Obesity (Lond). 2009;33:1446-1453.